LICHTSTRASSE 35, BASEL, V8
Remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials
Material disclosure
Delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint
First Quarter 2026 Condensed Interim Financial Report – Supplementary Data
Files Report on Form 6-K Dated March 18, 2026
Reports on Form 6-K dated February 4, 2026
Fourth Quarter and Full Year 2025 Condensed Financial Report – Supplementary Data
Receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)
Annual and Transition Report of Foreign Private Issuers
Amended Annual and Transition Report of Foreign Private Issuers
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Tender Offer Statement by Third Party
Tender Offer Statement by Issuer
Definitive Additional Information Statement
Notice of Proposed Sale of Securities
Initial Statement of Beneficial Ownership
Schedule 13G - Ownership Report
Amended Schedule 13D - Ownership Report
Free Writing Prospectus
Iran Notice
S-8 POS
Amended Tender Offer Statement by Third Party